Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy

R. J. Couzi, K. J. Helzlsouer, John H Fetting

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the prevalence and severity of vasomotor, gynecologic, and other symptoms among breast cancer patients, their health concerns, beliefs about estrogen replacement therapy (ERT), and willingness to take estrogen under medical supervision. Materials and Methods: A questionnaire was mailed to 320 women aged 40 to 65 years and diagnosed with in situ or invasive locoregional breast cancer in the years 1988 to 1992. Results: Of 222 eligible respondents, 190 were post-menopausal. The prevalence of symptoms among the postmenopausal women was as follows: hot flashes, 65%; night sweats, 44%; vaginal dryness, 48%; dyspareunia, 26%; difficulty sleeping, 44%; and feeling depressed, 44%. The latter two symptoms increased in frequency with increasing severity of vasomotor symptoms (P for trend ≤ .001). Forty-one percent of menopausal women perceived that they had experienced, since their breast cancer diagnosis, a physical or emotional problem related to menopause. Of these women, 50% felt they needed treatment. Overall, 31% of postmenopausal women would consider taking estrogen. Those who perceived that they had experienced a menopausal problem were more likely to consider estrogen than those who did not (42% v 22%, P = .003). The proportions willing to take estrogen increased with increasing severity of symptoms, particularly feelings of depression and sleep disturbance (P for trend = .008 and .007, respectively). Awareness that estrogen decreases the risks of heart disease and osteoporosis was not associated with an increased willingness to take it. However, beliefs that estrogen increases the risks of recurrent breast cancer and uterine cancer were associated with a decreased willingness to take it (P = .003 and .08, respectively). Conclusion: Vasomotor symptoms have a significant impact on the quality of life of breast cancer patients. Clinical trials to determine the safest and most effective ways to relieve these symptoms are needed.

Original languageEnglish (US)
Pages (from-to)2737-2744
Number of pages8
JournalJournal of Clinical Oncology
Volume13
Issue number11
StatePublished - 1995

Fingerprint

Estrogen Replacement Therapy
Estrogens
Breast Neoplasms
Emotions
Hot Flashes
Dyspareunia
Uterine Neoplasms
Sweat
Menopause
Osteoporosis
Heart Diseases
Sleep
Quality of Life
Clinical Trials
Depression
Health

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. / Couzi, R. J.; Helzlsouer, K. J.; Fetting, John H.

In: Journal of Clinical Oncology, Vol. 13, No. 11, 1995, p. 2737-2744.

Research output: Contribution to journalArticle

@article{7cf4a8dae6934cdb965591370a255471,
title = "Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy",
abstract = "Purpose: To determine the prevalence and severity of vasomotor, gynecologic, and other symptoms among breast cancer patients, their health concerns, beliefs about estrogen replacement therapy (ERT), and willingness to take estrogen under medical supervision. Materials and Methods: A questionnaire was mailed to 320 women aged 40 to 65 years and diagnosed with in situ or invasive locoregional breast cancer in the years 1988 to 1992. Results: Of 222 eligible respondents, 190 were post-menopausal. The prevalence of symptoms among the postmenopausal women was as follows: hot flashes, 65{\%}; night sweats, 44{\%}; vaginal dryness, 48{\%}; dyspareunia, 26{\%}; difficulty sleeping, 44{\%}; and feeling depressed, 44{\%}. The latter two symptoms increased in frequency with increasing severity of vasomotor symptoms (P for trend ≤ .001). Forty-one percent of menopausal women perceived that they had experienced, since their breast cancer diagnosis, a physical or emotional problem related to menopause. Of these women, 50{\%} felt they needed treatment. Overall, 31{\%} of postmenopausal women would consider taking estrogen. Those who perceived that they had experienced a menopausal problem were more likely to consider estrogen than those who did not (42{\%} v 22{\%}, P = .003). The proportions willing to take estrogen increased with increasing severity of symptoms, particularly feelings of depression and sleep disturbance (P for trend = .008 and .007, respectively). Awareness that estrogen decreases the risks of heart disease and osteoporosis was not associated with an increased willingness to take it. However, beliefs that estrogen increases the risks of recurrent breast cancer and uterine cancer were associated with a decreased willingness to take it (P = .003 and .08, respectively). Conclusion: Vasomotor symptoms have a significant impact on the quality of life of breast cancer patients. Clinical trials to determine the safest and most effective ways to relieve these symptoms are needed.",
author = "Couzi, {R. J.} and Helzlsouer, {K. J.} and Fetting, {John H}",
year = "1995",
language = "English (US)",
volume = "13",
pages = "2737--2744",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy

AU - Couzi, R. J.

AU - Helzlsouer, K. J.

AU - Fetting, John H

PY - 1995

Y1 - 1995

N2 - Purpose: To determine the prevalence and severity of vasomotor, gynecologic, and other symptoms among breast cancer patients, their health concerns, beliefs about estrogen replacement therapy (ERT), and willingness to take estrogen under medical supervision. Materials and Methods: A questionnaire was mailed to 320 women aged 40 to 65 years and diagnosed with in situ or invasive locoregional breast cancer in the years 1988 to 1992. Results: Of 222 eligible respondents, 190 were post-menopausal. The prevalence of symptoms among the postmenopausal women was as follows: hot flashes, 65%; night sweats, 44%; vaginal dryness, 48%; dyspareunia, 26%; difficulty sleeping, 44%; and feeling depressed, 44%. The latter two symptoms increased in frequency with increasing severity of vasomotor symptoms (P for trend ≤ .001). Forty-one percent of menopausal women perceived that they had experienced, since their breast cancer diagnosis, a physical or emotional problem related to menopause. Of these women, 50% felt they needed treatment. Overall, 31% of postmenopausal women would consider taking estrogen. Those who perceived that they had experienced a menopausal problem were more likely to consider estrogen than those who did not (42% v 22%, P = .003). The proportions willing to take estrogen increased with increasing severity of symptoms, particularly feelings of depression and sleep disturbance (P for trend = .008 and .007, respectively). Awareness that estrogen decreases the risks of heart disease and osteoporosis was not associated with an increased willingness to take it. However, beliefs that estrogen increases the risks of recurrent breast cancer and uterine cancer were associated with a decreased willingness to take it (P = .003 and .08, respectively). Conclusion: Vasomotor symptoms have a significant impact on the quality of life of breast cancer patients. Clinical trials to determine the safest and most effective ways to relieve these symptoms are needed.

AB - Purpose: To determine the prevalence and severity of vasomotor, gynecologic, and other symptoms among breast cancer patients, their health concerns, beliefs about estrogen replacement therapy (ERT), and willingness to take estrogen under medical supervision. Materials and Methods: A questionnaire was mailed to 320 women aged 40 to 65 years and diagnosed with in situ or invasive locoregional breast cancer in the years 1988 to 1992. Results: Of 222 eligible respondents, 190 were post-menopausal. The prevalence of symptoms among the postmenopausal women was as follows: hot flashes, 65%; night sweats, 44%; vaginal dryness, 48%; dyspareunia, 26%; difficulty sleeping, 44%; and feeling depressed, 44%. The latter two symptoms increased in frequency with increasing severity of vasomotor symptoms (P for trend ≤ .001). Forty-one percent of menopausal women perceived that they had experienced, since their breast cancer diagnosis, a physical or emotional problem related to menopause. Of these women, 50% felt they needed treatment. Overall, 31% of postmenopausal women would consider taking estrogen. Those who perceived that they had experienced a menopausal problem were more likely to consider estrogen than those who did not (42% v 22%, P = .003). The proportions willing to take estrogen increased with increasing severity of symptoms, particularly feelings of depression and sleep disturbance (P for trend = .008 and .007, respectively). Awareness that estrogen decreases the risks of heart disease and osteoporosis was not associated with an increased willingness to take it. However, beliefs that estrogen increases the risks of recurrent breast cancer and uterine cancer were associated with a decreased willingness to take it (P = .003 and .08, respectively). Conclusion: Vasomotor symptoms have a significant impact on the quality of life of breast cancer patients. Clinical trials to determine the safest and most effective ways to relieve these symptoms are needed.

UR - http://www.scopus.com/inward/record.url?scp=0028817824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028817824&partnerID=8YFLogxK

M3 - Article

C2 - 7595732

AN - SCOPUS:0028817824

VL - 13

SP - 2737

EP - 2744

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -